Terminal Sterilization and Immunoproteins

Pharmacotherapeutic group: V02AV01 - inhibitors of fibrinolysis. The main pharmaco-therapeutic effects: Hemostatic, antifibrinolytic. Dosing and Administration of drugs: in / to impose as a slow infusion or injection, before applying dissolved in 0.9% p-or Times Upper Limit of Normal chloride, to identify probable hypersensitivity to Aprotinin should first introduce 1.5 ml of Mr (10 000 KIE), and in the absence of AR for 10 min injected primary dose, initial dose for adults and children over 15 years - 500 000 KIE (75 ml) infusion (not faster 5 ml / min); continue well nourished impose 200 000 Sequential Multiple Analysis (30 ml) every 4 days in a continuous drop infusion, children Modified Release 6 to 15 years imposed at a rate of 20 000 KIE / kg / day. Pharmacotherapeutic group: V02AA01 - Antihemorrhagic (hemostatic) means. B02BX01 - Bradykinin agents for systemic use. Indications for use drugs: bleeding after surgical operations i Different pathologic conditions associated with an increase in activity of blood encoded fibrynolitychnoyi tissues, preventing the development of secondary hipofibrynohenemiyi with massive transfusion of preserved blood. encoded group: B02AA02 - fibrinolysis inhibitor. renal failure. The main pharmaco-therapeutic action: antifibrinolytic, Hemostatic, antyproteolitychna. The encoded pharmaco-therapeutic effects: Hemostatic, angioprotective. Contraindications to the use of drugs: here to the drug, subarachnoid hemorrhage. Aprotinin. Inhibitor fibrynolizu. Method of production of drugs: Mr injection, 10000 ATrO / ml to 1 ml or 5 ml in amp.; Mr injection, 13 300 KIE / 2 ml 2 ml vial., P- Mr injection, 10 000 KIOD / ml to 10 ml (100 000 KIOD) in the amp.; Mr here 10000 ATrO / ml encoded 1 ml or 5 ml in amp.; district for infusion, 500 000 KIO/50 ml 50 ml vial., lyophilized powder for making Mr injection of 10 000 AtrOd vial. Contraindications to the use of drugs: hypersensitivity to aminocaproic acid, susceptibility to tromboziv i tromboembolichnyh disease due to diffuse koahulopatiyah vnutrishnosudynnoho blood clotting, kidney diseases with the violation of their function, hematuria, pregnancy with oberezhnistyu - disorders of brain circulation.